Achieve Life Sciences Stock Price, News & Analysis (NASDAQ:ACHV)

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Achieve Life Sciences shares reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.

Achieve Life Sciences Inc (NASDAQ:ACHV) issued its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.17. View Achieve Life Sciences' Earnings History.

Achieve Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Achieve Life Sciences.

2 Wall Street analysts have issued 12 month target prices for Achieve Life Sciences' stock. Their predictions range from $6.00 to $20.00. On average, they expect Achieve Life Sciences' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 480.4% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.

Media headlines about ACHV stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achieve Life Sciences earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Achieve Life Sciences.

Achieve Life Sciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 391,200 shares, an increase of 8.3% from the July 31st total of 361,300 shares. Based on an average trading volume of 189,500 shares, the days-to-cover ratio is currently 2.1 days. Currently, 6.0% of the shares of the company are sold short. View Achieve Life Sciences' Current Options Chain.

Some companies that are related to Achieve Life Sciences include Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), GeneNews (GNWSF), Arca Biopharma (ABIO), Akers Biosciences (AKER), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Novavax (NVAX), SLS International (SLS), Immunomedics (IMMU), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Verastem (VSTM), Arena Pharmaceuticals (ARNA), Celldex Therapeutics (CLDX) and Amicus Therapeutics (FOLD).

Achieve Life Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sio Capital Management LLC (6.48%), Renaissance Technologies LLC (3.97%), Vanguard Group Inc. (3.39%), Searle & CO. (1.93%), Worth Venture Partners LLC (0.89%) and Jane Street Group LLC (0.21%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart. View Institutional Ownership Trends for Achieve Life Sciences.

ACHV stock was sold by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC. View Insider Buying and Selling for Achieve Life Sciences.

ACHV stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sio Capital Management LLC, Searle & CO., Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund and Richard Alistair Stewart. View Insider Buying and Selling for Achieve Life Sciences.

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHV stock can currently be purchased for approximately $2.24.

Achieve Life Sciences has a market capitalization of $18.14 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-12,690,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.View Additional Information About Achieve Life Sciences.

The official website for Achieve Life Sciences is http://www.achievelifesciences.com/.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]